TITLE

Quality of Life in 650 Lung Cancer Survivors 6 Months to 4 Years After Diagnosis

AUTHOR(S)
Svobodnik, Adam; Ping Yang; Novotny, Paul J.; Bass, Eric; Garces, Yolanda I.; Jeit, James R.; Bonner, James A.; Sloan, Jeff A.
PUB. DATE
August 2004
SOURCE
Mayo Clinic Proceedings;Aug2004, Vol. 79 Issue 8, p1024
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To present the results of a quality-of-life (QOL) assessment performed with the current version of the Lung Cancer Symptom Scale (LCSS) questionnaire in a large single-Institutional data set of 650 patients with lung cancer. PATIENTS AND METHODS: The study group included 650 patients with pathologically confirmed primary lung cancer whose conditions were diagnosed and/or treated at the Mayo Clinic in Rochester, Minn. between January 1, 1997, and December 31, 2001. The QOL assessment was performed using the self-administered LCSS questionnaire (version 2) 6 months to 4 years after the diagnosis of lung cancer. RESULTS: The item response rate for all 9 LCSS questions was 94.2% with a minimum of 92.9%. Significant differences in overall QOL by sex (P=-.04), Karnofsky scale (P<.001), weight loss (P<.001), disease stage (P<.001), and histology (P=.001) were found, but no significant differences in overall QOL by age (P=-.17) or marital status (P=.06) were observed. CONCLUSION: Our data suggest that QOL in patients with lung cancer at varying times after diagnosis highly correlates with baseline prognostic factors (disease stage, histology, Karnofsky scale, weight loss, and sex).
ACCESSION #
14201664

 

Related Articles

  • Clinical applications of circulating tumor cells in lung cancer patients by CellSearch system. Truini, Anna; Alama, Angela; Dal Bello, Maria Giovanna; Coco, Simona; Vanni, Irene; Rijavec, Erika; Genova, Carlo; Barletta, Giulia; Biello, Federica; Grossi, Francesco // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that might represent an important biomarker in lung cancer. The prognosis of patients diagnosed with lung cancer is generally poor mainly due to late diagnosis. Recent evidences have reported that tumor...

  • The Incidence of Hyponatraemia and Its Effect on the ECOG Performance Status among Lung Cancer Patients. SENGUPTA, AMITABHA; BANERJEE, SOURINDRA NATH; BISWAS, NIRENDRA MOHAN; JASH, DEBRAJ; SAHA, KAUSHIK; MAJI, ARNAB; BANDYOPADHYAYA, ANKAN; AGARWAL, SANDIP // Journal of Clinical & Diagnostic Research;Aug2013, Vol. 7 Issue 8, p1678 

    Context: Hyponatraemia is one of the common electrolytic disorders which are associated with lung cancer. Hyponatraemia may influence the ECOG performance status at presentation. Also, to the best of our knowledge, we found only limited Indian studies where the ECOG score was correlated with the...

  • Prognosis and Diagnosis.  // Current Medical Literature: Lung Cancer;2011, Vol. 4 Issue 3, p88 

    The article discusses several studies on lung cancer prognosis and diagnosis. A retrogressive study investigated the long term survival and risk factors for recurrence in stage I non-small cell lung cancer patients with tumors up to three centimeter maximum dimension. Another study examined the...

  • Does knowledge of cancer diagnosis affect quality of life? A methodological challenge. Montazeri, Ali; Hole, David J.; Milroy, Robert; McEwen, James; Gillis, Charles R. // BMC Cancer;2004, Vol. 4, p21 

    Background: As part of an assessment of quality of life in lung cancer patients an investigation was carried out to examine whether the knowledge of their diagnosis affected their quality of life. Methods: Every patient in a defined geographical area with a potential diagnosis of lung cancer was...

  • Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer. Linden, Philip // Current Medical Literature: Lung Cancer;2013, Vol. 7 Issue 2, p56 

    The article discusses research on the significance of lymph node involvement in the prognosis of stage II-N1 non-small-cell lung cancer (NSCLC). It references the study "Prognostic Significance of the Extent of Lymph Node Involvement in Stage II-N1 Non-Small Cell Lung Cancer," by Li Z. M. and...

  • Diagnosis and Prognosis.  // Current Medical Literature: Lung Cancer;2012, Vol. 6 Issue 1, p11 

    The article discusses studies published in medical journals about lung cancer diagnosis and prognosis. One study showed the association of the number of lymph nodes and metastatic lymph nodes with survival in lung cancer. Another study focused on a diagnostic program for patients suspected of...

  • A meta-analysis of comprehensive care on quality of life in patients with lung cancer. Xiang Wang; Haili Cao // Journal of Cancer Research & Therapeutics;2015 Sepcial Issue1, Vol. 11, pC112 

    Objective: The aim of this meta-analysis was to evaluate the efficacy of comprehensive care on quality of life in patients with lung cancer. Methods: The clinical studies about comprehensive care on quality of life in patients with lung cancer were searched in the Medline, PubMed, EMBASE, CNKI,...

  • Quality of life during chemotherapy in lung cancer patients: results across different treatment lines. Wintner, L M; Giesinger, J M; Zabernigg, A; Sztankay, M; Meraner, V; Pall, G; Hilbe, W; Holzner, B // British Journal of Cancer;10/29/2013, Vol. 109 Issue 9, p2301 

    Background:Most lung cancer patients are diagnosed at an advanced disease stage and predominantly receive palliative treatment, which increasingly consists of several chemotherapy lines. We report on patients' quality of life (QOL) to gain knowledge on QOL during and across multiple lines of...

  • Medical complexity and time to lung cancer treatment - a three-year retrospective chart review. Stokstad, Trine; Sørhaug, Sveinung; Amundsen, Tore; Grønberg, Bjørn H. // BMC Health Services Research;1/17/2017, Vol. 17, p1 

    Background: The time from a referral for suspected lung cancer is received at a hospital until treatment start has been defined as a quality indicator. Current Norwegian recommendation is that ≥70% should start surgery or radiotherapy within 42 calendar days and systemic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics